DiaSorin S.p.A. (FRA:34D)

Market Cap	3.31B
Revenue (ttm)	1.21B
Net Income (ttm)	184.11M
Shares Out	n/a
EPS (ttm)	3.41
PE Ratio	17.97
Forward PE	13.78
Dividend	1.20 (1.95%)
Ex-Dividend Date	May 19, 2025

Volume	n/a
Average Volume	85
Open	61.46
Previous Close	60.66
Day's Range	61.46 - 61.46
52-Week Range	58.12 - 107.20
Beta	n/a
RSI	36.78
Earnings Date	Mar 13, 2026

About DiaSorin

DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, endocrinology, gastrointestinal infections, autoimmunity, hypertension, emergency/sepsis, bone metabolism, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urin...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1968
• Employees: 3,308
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 34D

Financial Performance

In 2024, DiaSorin's revenue was 1.19 billion, an increase of 3.24% compared to the previous year's 1.15 billion. Earnings were 188.11 million, an increase of 17.68%.